Deletion of the long arm of chromosome 11 (11q deletion) is one of the most frequent events
that occur during the development of aggressive neuroblastoma. Clinically, 11q deletion is …

Neuroblastoma (NB) is an embryonal tumor of the sympathetic nervous system which
accounts for 8–10% of pediatric cancers. It is characterized by a broad spectrum of clinical …

High-risk neuroblastoma is a very aggressive disease, with excessive tumor growth and
poor outcomes. A proper stratification of the high-risk patients by prognostic outcome is …

Neuroblastoma serves as a paradigm for utilising tumour genomic data for determining
patient prognosis and treatment allocation. However, before the establishment of the …

Purpose For a comprehensive overview of the genetic alterations of neuroblastoma, their
association and clinical significance, we conducted a whole-genome DNA copy number …

Analysis of chromosomal aberrations is used to determine the prognosis of neuroblastomas
(NBs) and to aid treatment decisions. MYCN amplification (MNA) alone is an incomplete …

Background: In the INRG dataset, the hypothesis that any segmental chromosomal alteration
might be of prognostic impact in neuroblastoma without MYCN amplification (MNA) was …

Purpose Neuroblastoma is characterized by two distinct types of genetic profiles, consisting
of either numerical or segmental chromosome alterations. The latter are associated with a …

Motivation: Analyzing data from multi-platform genomics experiments combined with
patients' clinical outcomes helps us understand the complex biological processes that …

Neuroblastoma shows complex patterns of genetic aberrations including MYCN
amplification, deletion of chromosome 1p or 11q, and gain of chromosome 17q. The 17q …